The two CPE-upregulating agomirs would have considerable clinical implications for AD as they could increase both adult neurogenesis and mBDNF levels in the hippocampus, and more importantly, could reverse the behavioral and neurocognitive declines in APP/PS1 mice even delivered via a non-invasive intranasal instillation approach. The gene discussed is APP; the disease is Alzheimer disease.